The first 2 authors contributed equally to this manuscript.
Radiofrequency ablation versus open hepatic resection for elderly patients (> 65 years) with very early or early hepatocellular carcinoma
Article first published online: 6 AUG 2013
© 2013 American Cancer Society
Volume 119, Issue 21, pages 3812–3820, 1 November 2013
How to Cite
Peng, Z.-W., Liu, F.-R., Ye, S., Xu, L., Zhang, Y.-J., Liang, H.-H., Lin, X.-J., Lau, W. Y. and Chen, M.-S. (2013), Radiofrequency ablation versus open hepatic resection for elderly patients (> 65 years) with very early or early hepatocellular carcinoma. Cancer, 119: 3812–3820. doi: 10.1002/cncr.28293
- Issue published online: 18 OCT 2013
- Article first published online: 6 AUG 2013
- Manuscript Accepted: 25 JUN 2013
- Manuscript Revised: 19 JUN 2013
- Manuscript Received: 5 APR 2013
- elderly patients;
- hepatocellular carcinoma;
- radiofrequency ablation;
This study retrospectively compared the safety and efficacy of percutaneous radiofrequency ablation (RFA) with open hepatic resection (HR) in elderly patients (age > 65 years) with very early or early hepatocellular carcinoma (HCC).
Elderly patients (n = 180) with very early or early HCC were studied. This study was approved by the Ethics Committee of the Cancer Center of Sun Yat-Sen University, Guangzhou, China. Written informed consent was obtained from each patient before treatment. As an initial treatment, 89 patients were treated by RFA and 91 patients by HR. The survival curves were constructed by the Kaplan-Meier method and compared by log-rank test.
The 1-, 3-, and 5-year overall survivals were 93.2%, 71.1%, and 55.2% for the RFA group and 88.8%, 62.8%, and 51.9% for the HR group, respectively (P = .305). The corresponding recurrence-free survivals for these 2 groups were 84.1%, 62.7%, and 35.5% and 76.7%, 39.3%, and 33.1%, respectively (P = .035). On subgroup analysis for tumor ≤ 3 cm, the 1-, 3-, and 5-year overall survivals were 94.2%, 82.6%, and 67.5% for the RFA group and 90.1%, 65.0%, and 55.1% for the HR group, respectively (P = .038). The corresponding recurrence-free survivals for the 2 groups were 85.5%, 69.1%, and 40.7%, and 82.2%, 40.1%, and 31.8%, respectively (P = .049). For tumor > 3 cm, there was no significant difference between these 2 groups for overall survivals and recurrence-free survivals (P = .543, P = .356, respectively). A multivariate regression analysis showed that treatment type was the only significant prognostic factor for recurrence-free survival (P = .039).
There was no difference between the HR and RFA groups for overall survival, but RFA had better efficacy than HR for elderly patients with HCC ≤ 3 cm. Cancer 2013;119:3812–3820. © 2013 American Cancer Society.